Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Nurse, Pharmacist, Respiratory Therapist
Target Specialties: Oncology, Hematology/Oncology

Leah Naghi

City of Hope
Assistant Clinical Professor

Medical oncologist Leah Naghi, M.D., applies her interest in genetics to precision oncology for breast cancer patients, enjoying connecting with them and working to ensure they are partners in mapping out their individual treatment plans.

Dr. Naghi pursued her medical degree at the University of Southern California, then completed an internal medicine residency at New York’s Montefiore Medical Center. She came to City of Hope® for a fellowship in hematology and medical oncology, where she served as chief fellow. She has also completed City of Hope’s Intensive Course in Genetic Cancer Risk Assessment.

Her research includes investigations into hereditary cancer risk, including real world performance of genetic testing guidelines in multiethnic populations; mutation patterns in a large cohort of patients with hematologic malignancies; and treatment outcomes in breast cancer patients with actionable mutations. As part of her work in the lab led by the founding director of City of Hope's center for Precision Medicine, she presented research on enhanced screening practices of women after multiplex gene panel testing at the 2022 San Antonio Breast Cancer Symposium. She has also presented her research internationally.